BMEA — Biomea Fusion Share News
0.000.00%
Last trade - 00:00Brief: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-Generation Oral Small Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion To Announce Phase I Results For Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities
Brief: Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes
Biomea Fusion, Inc. reports results for the quarter ended June 30 - Earnings Summary
Biomea Fusion Q2 loss narrows, cash runway into Q2 2027
Biomea Fusion Inc expected to post a loss of 22 cents a share - Earnings Preview
Brief: Biomea Fusion Says Icovamenib Data Show Muscle Preservation And Fat Reduction In Obesity And Diabetes
Biomea Fusion Q1 net loss narrows as expenses fall
Brief: Biomea Fusion Announces Poster Presentations Of Icovamenib At The American Diabetes Association (Ada) 86Th Scientific Sessions
U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies
U.S. STOCKS ON THE MOVE-Praxis, EUDA Health, Humana
U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Ulta Beauty, Victoria's Secret
Biomea Fusion rises as diabetes drug shows promise
U.S. RESEARCH ROUNDUP-Applied Materials Inc, Blackstone Mortgage, Brookdale Senior Living
Biomea Fusion Q3 net loss narrows
Brief: Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
U.S. RESEARCH ROUNDUP- AGCO, Caterpillar, United Rentals
U.S. STOCKS ON THE MOVE- Applovin, Ford Motor, Alto Neuroscience